Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

NEXT STORY
Agenus Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
PREV STORY
Infection Control Market Worth $58 billion by 2027, Growing at a CAGR of 13.3% From 2020, Says Meticulous Research®
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sun BioPharma Provides Business Update and Files Annual Report for 2018

author_avatar
NASDAQ Market News

Subcutaneous Drug Delivery Devices Market Is Expected to Generate Revenue Worth US$ 71 billion by 2030, Globally

author_avatar
NASDAQ Market News

UroGen Pharma Strengthens Management Team with the Appointment of Paul Chu as Vice President of Business Development

RA'ANANA, Israel, and NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. ...

author_avatar
NASDAQ Market News